Publication of Enhanced Bulbar Function in ALS: The Nuedexta Treatment Trial in Neurotherapeutics, 14(3), 762-772.
The recently published article is noteworthy in that the placebo-controlled multi-centered study demonstrated enhanced speech and swallowing in response to treatments with Nuedexta which was approved in 2011 for the treatment of labile emotionality that occurs in ALS and kindred disorders. To our knowledge, this is the first controlled study to show improvement of function in ALS patients using a therapeutic agent. If confirmed in a longer and larger study, Nuedexta is likely to play an important role in the treatment of ALS in addition to its effect on labile emotionality.